Printer Friendly

GPC Biotech licenses reverse genomics technology from ARIAD.

GPC Biotech AG (Martinsried/Munich, Germany) announced it has licensed intellectual property to further expand the patent estate for its Reverse Genomics technology platform. GPC Biotech has signed a non-exclusive license agreement with ARIAD Pharmaceuticals, Inc. (Cambridge, MA) that allows GPC Biotech to use intellectual property from ARIAD's proprietary ARGENT cell-signaling regulation technology in GPC Biotech's proprietary LeadCode drug discovery and Reverse Genomics platform. GPC Biotech holds a significant intellectual property position for LeadCode.

LeadCode is a proprietary drug-target interaction screening technology developed by GPC Biotech that can be applied across a broad range of compounds and disease areas. It is part of the company's Reverse Genomics platform, which is focused on addressing bottlenecks at later stages of the drug discovery process and uses discovery technologies to understand how drugs impact the body to improve drug design. LeadCode enables biopharmaceutical companies to effectively leverage existing product portfolios and reduce attrition of drug discovery programs. The technology is designed to identify and analyze the interaction of a small molecule, such as a drug, with the full complement of human proteins. LeadCode can define the mechanism-of-action of a particular molecule and identify possible toxic effects, which are critical to understanding that compound's potential as an effective treatment for a specific disease.

GPC Biotech will be applying LeadCode to its internal drug discovery and development efforts, as well as commercializing the technology for use by the biopharmaceutical industry. On January 31, 2003, GPC Biotech announced its first alliance using LeadCode. That collaboration is with Eli Lilly and company to elucidate the mechanism-of-action of a class of compounds that Lilly is developing in the area of metabolic diseases.

GPC Biotech AG is a biotechnology company dedicated to discovering and developing new anticancer drugs through innovative discovery technologies and development approaches. The company's lead product candidate -- satraplatin -- has successfully completed Phase 2 clinical trials and is expected to enter Phase 3 registrational studies during 2003. The company is leveraging its drug discovery technologies in novel ways to elucidate the mechanisms-of-action of drug candidates and to support the growth of its drug pipeline. Drug discovery and development alliance partners include: ALTANA Pharma of ALTANA AG, Aventis Pharma, Boehringer Ingelheim International GmbH, Eli Lilly and Company, MorphoSys AG, PanTherix Ltd., and Spectrum Pharmaceuticals, Inc.

GPC Biotech AG +49 (0)89 8565-2600 www.gpc-biotech.com
COPYRIGHT 2003 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:GPC Biotech licenses reverse genomics technology from ARIAD.
Publication:BIOTECH Patent News
Geographic Code:4EUGE
Date:Feb 1, 2003
Words:387
Previous Article:Celgene expands kinase patent estate.
Next Article:University of Nebraska obtains United States patent.
Topics:


Related Articles
GPC Biotech announces issuance of United States patent for detecting diseased cells.
GPC BIOTECH GETS GERMANY PERMITS FOR MONOCLONAL ANTIBODY.
GBC BIOTECH PRESENTS NEW DATA ON EFFICACY OF SATRAPLATIN.
GPC BIOTECH GETS U.S. PATENT FOR ANTI-CANCER CELL INHIBITOR.
GPC BIOTECH/DEBIOPHARM SIGN MHC II ANTAGONISTS LICENSE PACT.
GPC Biotech and Ingenium receive joint drug discovery grant from German government.
GPC BIOTECH PRESENTS NEW SATRAPLATIN DATA AT AACR.
Pharmion and GPC Biotech announce partnering agreement for prostate cancer treatment.
SATRAPLATIN REDUCES RISK OF PROSTATE CANCER PROGRESSION.
GPC BIOTECH MARKETING AUTHORIZATION APPLICATION WITHDRAWN.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters